Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Strides Shasun gets...

    Strides Shasun gets USFDA approval for Ibuprofen and Milnacipran Hydrochloride tablets

    Written by Ruby Khatun Khatun Published On 2018-07-05T10:15:07+05:30  |  Updated On 5 July 2018 10:15 AM IST
    Strides Shasun gets USFDA approval for Ibuprofen and Milnacipran Hydrochloride tablets

    New Delhi: Drug firm Strides Shasun said it has received approval from the US health regulator for anti-inflammatory Ibuprofen tablets and for Milnacipran Hydrochloride tablets used for treating pain due to a certain condition.


    Company's arm Strides Pharma Global has received final approval for Ibuprofen tablets USP, 200 mg from the United States Food & Drug Administration (USFDA), Strides Shasun said in a filing to BSE.




    The product is a generic version of Johnson & Johnson Consumer Inc's Motrin IB tablets in the same strength, it added.


    The tablets will be manufactured at the company's oral dosage facility at Puducherry and will be marketed by Strides Pharma Inc in the US, Strides Shasun said.


    "The approval further strengthens Strides Ibuprofen franchise for the US markets that now comprises 7 approved products addressing a combined Rx and OTC opportunity of USD 900 million as per IMS and IRI data," it added.


    Ibuprofen is used to relieve a headache, dental pain, muscle aches, or arthritis. It is also used to reduce fever and to relieve minor aches and pain due to common cold or flu, the company said.


    Strides Pharma Global has also received tentative approval from USFDA for its Para IV filing of Milnacipran Hydrochloride tablets in the strengths of 12.5 mg, 25 mg, 50 mg, and 100 mg, Strides Shasun said.


    The product is a generic version of Allergan Sales LLC's Savella tablets, it added.


    "As per IQVIA MAT data, the US market for Milnacipran Hydrochloride tablets is approximately USD 145 million," Strides Shasun said.


    The product will be manufactured at the company's oral dosage facility at Puducherry and marketed by Strides Pharma Inc in the US market, it added.


    Milnacipran Hydrochloride tablet is used to treat pain caused by a condition called fibromyalgia that affects muscles, tendons, ligaments, and supporting tissues, Strides Shasun said.


    The company has 75 cumulative abbreviated new drug application (ANDA) filings with USFDA of which 51 have been approved as of date and 24 are pending approval, it added.

    abbreviated new drug applicationsAllergananti-inflammatory drugapprovalgeneric versionIbuprofen tabletsJohnson and JohnsonMilnacipran Hydrochloride tabletsMotrin IB tabletspainSavella tabletsStrides Pharma GlobalStrides ShasunUnited States Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok